TScan Therapeutics, Inc. (TCRX)

7.22 +0.10 (+1.40%) As of 01:34PM EDT. Market open.

TScan Therapeutics, Inc.

830 Winter Street
Waltham, MA 02451
United States
857 399 9500
https://www.tscan.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 154

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gavin MacBeath Ph.D.	CEO & Director	853.51k	N/A	1970
Dr. Zoran Zdraveski J.D., Ph.D.	Chief Legal & Strategy Officer and Company Secretary	657.2k	N/A	1970
Dr. Stephen J. Elledge Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Mr. Tomasz Kula Ph.D.	Co-Founder & Member of Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Corporate governance

TScan Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.